.png)
.webp)
In 1999, the prominent American healthcare services company McKesson Corporation significantly expanded its footprint in the medical information systems sphere by acquiring HBO & Company (HBOC) for $14.5 billion.
HBOC was a major player in the healthcare software industry, providing integrated software and services to hospitals, medical practices, and insurance providers across North America.
With high-flying growth and profits during the 1990s tech boom, the acquisition appeared a shrewd move for McKesson to capitalize on the accelerating digitization of medical records and patient care.
However, within just two years, major accounting irregularities were uncovered inside HBOC, leading to financial restatements and executive indictments.
The deal that once seemed to solidify McKesson's technological future nearly threatened the stability of the entire company in the short term.
Though McKesson rapidly moved to integrate and stabilization operations after the scandal, the monumental HBOC acquisition exemplified both the promises and perils of mergers in the fast-moving, high-stakes American healthcare sector as the millennium dawned.
Seeking to bounce back from earlier struggles after its problematic acquisition of HBOC in 1999, McKesson made a pair of high-profile health information technology purchases in 2006—Per Se Technologies for $500 million and RelayHealth for $480 million.
These substantial investments reflected McKesson's strategy of doubling down on healthcare software and services to drive higher-margin revenue growth compared to its traditional medical distribution business.
Per Se brought financial and administrative automation capabilities while RelayHealth specialized in online patient-provider connectivity and communication.
Together, they significantly bolstered McKesson's end-to-end IT offerings for hospitals, insurers, and physician practices as healthcare digitization accelerated.
Though representing sizable outlays, the acquisitions fueled McKesson's transformation into an integrated healthcare technology and distribution powerhouse, setting the stage for over a decade of sustained success to follow.
They highlighted both McKesson's resources and its farsighted vision in reshaping itself for the increasingly tech-centric medical landscape at the dawn of the 21st century’s second decade.
McKesson continued its aggressive expansion in healthcare information technologies with the purchase of medical practice management software firm Practice Partner in 2007.
Valued at over $150 million, the deal allowed McKesson to deepen its support for physicians’ offices, now offering practice management, medical records, scheduling, and billing solutions alongside its tools for hospitals and insurance providers.
The acquisition aligned with McKesson’s broader strategy to assemble an end-to-end healthcare IT portfolio spanning the entire patient care continuum.
It also reflected the steadily growing reliance on advanced health IT software to improve care coordination, operational efficiency, and cost-savings amidst complex industry dynamics.
With Practice Partner in the fold, McKesson gained specialized expertise and an installed base catering to small and mid-sized medical practices, setting the stage to accelerate adoption among this key healthcare sector while consolidating its position as a dominant player in health IT integration.
McKesson made a major move into cancer care services in 2010 with its $2.16 billion purchase of physician network US Oncology.
This substantial outlay secured McKesson an established network of over 1,400 oncology doctors treating over 750,000 cancer patients annually in communities across America.
It complemented McKesson’s strengths in hospital systems and health IT by expanding its capacity to provide integrated care coordination, clinical research, and support services tailored specifically for cancer patients.
The deal was also emblematic of a broader industry shift towards healthcare services consolidation and emerging value-based care models that incentivized quality over quantity.
Positioning itself at the forefront of cancer treatment innovation with US Oncology in its arsenal, McKesson was undertaking a pivotal diversification to reinforce its financial fortunes in the face of upcoming changes to traditional fee-for-service approaches in American healthcare.
McKesson took a major step towards European expansion in late 2013, agreeing to purchase a 50 percent ownership position in German healthcare services conglomerate Celesio for $8.3 billion.
Celesio operated wholesale pharmaceutical distribution and medical supply chains across Europe much like McKesson did in North America, while also owning thousands of pharmacies.
McKesson's costly investment signaled its appetite to gain an enhanced global footprint, establish an European base of operations, and capitalize on synergies between the two companies' logistics networks serving hospitals and pharmacies.
While Celesio faced some economic struggles in 2013, McKesson likely saw an opportune moment to secure a high-value strategic foothold in the European market—one of the world's largest healthcare regions—at a reasonable price.
The cross-continent move pointed to McKesson's ambition to fortify revenues and profits through broader geographic diversification.
Further building on nearly two decades of aggressive expansions in healthcare information technologies, McKesson in mid-2016 unveiled plans for a monumental IT division merger with Change Healthcare, then a division of hospital operator HCA.
The deal would have combined McKesson's medical software and analytics offerings with Change's revenue cycle management, imaging, and patient engagement tools to create one of the largest healthcare IT enterprises globally.
However, the projected cost savings and synergies between the massive companies failed to fully materialize after the merger.
Citing complex organizational alignment challenges, McKesson and Change Healthcare quietly split in early 2020, unwinding their high-profile union barely four years after its announcement.
The dissolution highlighted the immense difficulties of integrating complex health IT systems and company cultures even between organizations with complementary capabilities and resources.
Healthcare technology convergence remains an alluring but often elusive goal in practice for even the sector's most dominant giants like McKesson.
Expanding its formidable pharmacy footprint beyond the United States, McKesson struck a monumental $3 billion deal in 2016 to acquire Rexall Health from Canadian retail conglomerate Katz Group.
Rexall operated nearly 500 pharmacies across Canada plus related wholesale distribution servicing 1,300 more locations.
For McKesson, the acquisition realized a long-standing ambition to control an international pharmacy chain while also boosting its branding and reach in pharmaceutical distribution north of the American border.
The sizable investment demonstrated McKesson’s appetite for growth via vertical integration: combining Rexall’s stores with McKesson Canada’s existing back-end pharmaceutical supply chain dominance.
It also highlighted McKesson’s recognition of major trends reshaping community pharmacies amid changing consumer behaviors, including shifts towards specialty medications, chronic disease management services, preventative health, and wellness offerings.
The future viability and profitability of pharmacy retail would depend heavily on adaptation—with McKesson positioning itself at the vanguard of innovation via full-spectrum consolidations like the Rexall deal.
.png){kind=logo}
.webp)
.webp)
.webp)